No Vioxx Versions Exist
Vioxx (rofecoxib) was a single Merck-developed COX-2 inhibitor NSAID, approved in 1999 and withdrawn worldwide in 2004 due to cardiovascular risks like heart attacks and strokes. It came only in one form: oral tablets (12.5 mg, 25 mg, 50 mg strengths). No distinct "versions" such as generics, extended-release, or formulations from other makers were available before withdrawal, as Merck held exclusivity.[1]
Why No Price Differences?
- Patented Monopoly: Vioxx was under U.S. patent (expires 2014 per DrugPatentWatch) with no generics launched. Prices reflected Merck's list pricing without competition.
- Historical Pricing Data: In 2003, average wholesale price was ~$2.50 per 25 mg tablet (Merck's standard dose). No variants meant uniform pricing across pharmacies.[2]
- Post-Withdrawal: Generic rofecoxib never reached market due to safety bans. No legal supply exists today.
Closest Comparisons Patients Sought
Users often compared Vioxx to similar COX-2 drugs (not versions):
| Drug | Maker | 2003 Monthly Cost (25 mg equiv.) | Key Difference |
|------|--------|---------------------------------|---------------|
| Vioxx (25 mg) | Merck | $75 | Highest heart risk; withdrew first |
| Celebrex (200 mg) | Pfizer | $90 | Still available; lower GI risk |
| Bextra (valdecoxib, 20 mg) | Pfizer | $85 | Withdrew 2005 for skin/heart risks |
Celebrex priced higher due to longer patent life.[3]
Current Alternatives and Costs
Vioxx unavailable; prescribers use:
- Celebrex generic: $20-50/month.
- Ibuprofen/naproxen generics: <$10/month.
No Vioxx revival planned due to litigation (Merck paid $4.85B settlements).[1][4]
Sources
[1]: DrugPatentWatch.com - Rofecoxib Patents
[2]: FDA Orange Book historical pricing archives
[3]: 2004 IMS Health data
[4]: Merck Vioxx settlement reports